Adjuvant Chemotherapy for Patients with Stage III Colon Cancer: Results from a CDC-NPCR Patterns of Care Study

Objective To evaluate adjuvant chemotherapy use for Stage III colon cancer. Methods This analysis included 973 patients with surgically treated stage III colon cancer. Socioeconomic information from the 2000 census was linked to patients’ residential census tracts. Vital status through 12/31/02 was obtained from medical records and linkage to state vital statistics files and the National Death Index. Results Adjuvant chemotherapy was received by 67%. Treatment varied by state of residence, with Colorado, Rhode Island and New York residents more likely to receive chemotherapy than Louisiana residents. Older age, increasing comorbidities, divorced/widowed marital status, and residence in lower education areas or non-working class neighborhoods were associated with lower chemotherapy use. Survival varied by state but after adjustment for sex, sociodemographic and health factors, was significantly higher only for California and Rhode Island. Older age and lower educational attainment were associated with lower survival. Chemotherapy was protective for all comorbidity groups. Conclusion Although adjuvant chemotherapy for Stage III colon cancer improves survival, some patients did not receive standard of care, demonstrating the need for cancer treatment surveillance. Interstate differences likely resulted from differences in local practice patterns, acceptance of treatment, and access.

[1]  Susan Bolick-Aldrich,et al.  Rationale and design of the National Program of Cancer Registries' breast, colon, and prostate cancer patterns of care study , 2004, Cancer Causes & Control.

[2]  A. Zaslavsky,et al.  Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[4]  C. Lynch,et al.  Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Begg,et al.  Age and adjuvant chemotherapy use after surgery for stage III colon cancer. , 2001, Journal of the National Cancer Institute.

[6]  C. Fuchs,et al.  Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. , 2001, Journal of the National Cancer Institute.

[7]  Joseph V. Simone,et al.  Enhancing Data Systems to Improve the Quality of Cancer Care , 2000 .

[8]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[9]  N. Krieger.  Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. , 1992, American journal of public health.

[10]  Amy Trentham-Dietz,et al.  Quality of cancer registry data: findings from CDC-NPCR's Breast and Prostate Cancer Data Quality and Patterns of Care Study. , 2011, Journal of registry management.

[11]  Joseph V. Simone,et al.  Ensuring Quality Cancer Care , 1999 .

[12]  R. Deyo,et al.  ADAPTING A CLINICAL COMORBIDITY USE WITH ICD-g-CM ADMINISTRATIVE INDEX FOR DATABASES , 1992 .

[13]  Gerhard Jentzsch,et al.  Working group on , 1991 .

[14]  Adjuvant therapy for patients with colon and rectum cancer. , 1990, Consensus statement. National Institutes of Health Consensus Development Conference.